The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer

Roma Maguire (Lead / Corresponding author), Patricia A. Fox, Lisa McCann, Christine Miaskowski, Grigorios Kotronoulas, Morven Miller, Eileen Furlong, Emma Ream, Jo Armes, Elisabeth Patiraki, Alexander Gaiger, Geir V. Berg, Adrian Flowerday, Peter Donnan, Paul McCrone, Kathi Apostolidis, Jenny Harris, Stylianos Katsaragakis, Alison R. Buick, Nora Kearney

    Research output: Contribution to journalArticle

    36 Citations (Scopus)
    150 Downloads (Pure)

    Abstract

    Introduction: While some evidence exists that real-time remote symptom monitoring devices can decrease morbidity and prevent unplanned admissions in oncology patients, overall, these studies have significant methodological weaknesses. The electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology (eSMART) study is designed to specifically address these weaknesses with an appropriately powered, repeated-measures, parallel-group stratified randomised controlled trial of oncology patients.

    Methods and Analysis: A total of 1108 patients scheduled to commence first-line chemotherapy (CTX) for breast, colorectal or haematological cancer will be recruited from multiple sites across five European countries.Patients will be randomised (1:1) to the ASyMS intervention (intervention group) or to standard care currently available at each site (control group). Patients in the control and intervention groups will complete a demographic and clinical questionnaire, as well as a set of valid and reliable electronic patient-reported outcome measures at enrolment, after each of their CTX cycles (up to a maximum of six cycles) and at 3, 6, 9 and 12 months after completion of their sixth cycle of CTX. Outcomes that will be assessed include symptom burden (primary outcome), quality of life, supportive care needs, anxiety, self-care self-efficacy, work limitations and cost effectiveness and, from a health professional perspective, changes in clinical practice (secondary outcomes).

    Ethics and Dissemination: Ethical approval will be obtained prior to the implementation of all major study amendments. Applications will be submitted to all of the ethics committees that granted initial approval.eSMART received approval from the relevant ethics committees at all of the clinical sites across the five participating countries. In collaboration with the European Cancer Patient Coalition (ECPC), the trial results will be disseminated through publications in scientific journals, presentations at international conferences, and postings on the eSMART website and other relevant clinician and consumer websites; establishment of an eSMART website (www.esmartproject.eu) with publicly accessible general information; creation of an eSMART Twitter Handle, and production of a toolkit for implementing/utilising the ASyMS technology in a variety of clinical practices and other transferable health care contexts.

    Trial Registration Number: NCT02356081.

    Original languageEnglish
    Article numbere015016
    Pages (from-to)1-10
    Number of pages10
    JournalBMJ Open
    Volume7
    Issue number5
    DOIs
    Publication statusPublished - 1 May 2017

    Fingerprint Dive into the research topics of 'The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer'. Together they form a unique fingerprint.

  • Projects

    Cite this

    Maguire, R., Fox, P. A., McCann, L., Miaskowski, C., Kotronoulas, G., Miller, M., Furlong, E., Ream, E., Armes, J., Patiraki, E., Gaiger, A., Berg, G. V., Flowerday, A., Donnan, P., McCrone, P., Apostolidis, K., Harris, J., Katsaragakis, S., Buick, A. R., & Kearney, N. (2017). The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer. BMJ Open, 7(5), 1-10. [e015016]. https://doi.org/10.1136/bmjopen-2016-015016